Overview of Multiple System Atrophy

Jul 16, 2025

Overview

This lecture covers the diagnosis, clinical features, and treatment of Multiple System Atrophy (MSA), a rare neurodegenerative disease often mistaken for Parkinson’s disease but with distinctive features and more rapid progression.

Disease Overview & History

  • Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disease involving misfolded alpha-synuclein protein inclusions.
  • MSA has overlapping features with Parkinson’s disease but progresses more rapidly and lacks sustained response to levodopa.
  • Historically, MSA had several names, including Shy-Drager syndrome and olivopontocerebellar atrophy, reflecting affected brain regions.

Clinical Features & Diagnosis

  • MSA is characterized by parkinsonism (slow movement, rigidity), cerebellar signs (balance/gait problems), and severe autonomic dysfunction.
  • Early signs can include REM sleep behavior disorder, speech and swallowing problems, and early balance issues.
  • Diagnosis is difficult; no definitive biomarker exists—clinical criteria are relied upon.
  • MRI might show the "hot cross bun sign" in the pons, but it is not present in all cases.
  • MSA affects both sexes equally and mainly appears in people in their 50s-60s.
  • Disease progresses rapidly: 30% need walking aids within 3 years, 60% wheelchair-bound at 5 years.

Autonomic Dysfunction & Symptom Management

  • Autonomic dysfunction includes orthostatic hypotension (drop in blood pressure on standing), bladder/bowel problems, and impaired sweating.
  • Management includes increased water and salt intake, frequent small meals, and medications under medical supervision.
  • Bladder problems may require catheterization or medications; constipation managed with hydration, exercise, and stool softeners.
  • Pain, anxiety, depression, and sleep disturbances are common and need multidisciplinary management.

Treatment Approaches

  • Levodopa offers limited, short-lived improvement and can worsen blood pressure problems.
  • Multidisciplinary care involves neurologists, cardiologists, gastroenterologists, sleep specialists, psychologists, and rehabilitation therapists.
  • Physical, occupational, and speech therapy are essential to maintain mobility, independence, and address swallowing/speech issues.
  • Symptom management may also involve botox for dystonia, interventions for drooling, and careful monitoring for medication side effects.

Research & Future Directions

  • Few high-quality clinical trials have shown positive results; most therapies are symptomatic.
  • Current research focuses on stem cells, monoclonal antibodies targeting alpha-synuclein, neurotropic factors, and small molecule inhibitors.
  • Around 10 new clinical trials are recruiting; clinical trials.gov lists opportunities for patient participation.

Key Terms & Definitions

  • Multiple System Atrophy (MSA) — a rare, progressive disease with parkinsonism, cerebellar, and autonomic symptoms due to alpha-synuclein pathology.
  • Alpha-synuclein — a protein abnormally aggregated in MSA and Parkinson’s disease.
  • Autonomic Dysfunction — impairment of involuntary nervous system functions (blood pressure, bladder, bowel, etc.).
  • Orthostatic Hypotension — drop in blood pressure upon standing, causing dizziness or fainting.
  • Hot Cross Bun Sign — MRI finding in the pons suggestive of MSA.

Action Items / Next Steps

  • Consult with specialists for individualized management.
  • Increase water and small, frequent meals to manage blood pressure.
  • Perform daily physical and occupational therapy exercises.
  • Monitor clinicaltrials.gov for research participation opportunities.
  • Seek mental health support for both patients and caregivers.

Certainly! Here is a comprehensive, in-depth summary and review of the lecture on Multiple System Atrophy (MSA) by Dr. Teresa Zeswitz:

Comprehensive Summary and Review: Multiple System Atrophy (MSA) Lecture

Introduction and Background

Dr. Teresa Zeswitz, a neurologist and director of the USF Ataxia Research Center, presented an extensive overview of Multiple System Atrophy (MSA), a rare and devastating neurodegenerative disorder. MSA is often confused with Parkinson’s disease due to overlapping symptoms but is distinct in its pathology, clinical course, and treatment challenges.

Historical Context

  • MSA was historically known by various names reflecting the brain regions affected, such as Shy-Drager syndrome, striatonigral degeneration, and olivopontocerebellar atrophy.
  • The unifying term "Multiple System Atrophy" was coined in 1969 by Graham and Oppenheimer to emphasize the multisystem involvement of the disease.
  • Early 20th-century French neurologists first described the condition based on adult-onset sporadic ataxia and brainstem/cerebellar involvement.

Pathophysiology

  • MSA is characterized by the abnormal accumulation and misfolding of alpha-synuclein protein, similar to Parkinson’s disease, but with distinct pathological inclusions.
  • These misfolded proteins aggregate in multiple brain systems, including the basal ganglia, cerebellum, brainstem, and autonomic nervous system.
  • The multisystem involvement explains the complex clinical presentation involving motor, cerebellar, and autonomic symptoms.

Epidemiology

  • MSA is rare, with an incidence of approximately 1.6 cases per 100,000 people over 40 years old, increasing slightly with age.
  • It affects men and women equally.
  • Onset typically occurs in the sixth decade of life (50s-60s).

Clinical Presentation and Diagnosis

Motor Symptoms

  • Parkinsonism: Patients exhibit slow movement (bradykinesia), rigidity, and postural instability.
  • Unlike Parkinson’s disease, MSA patients have a poor or transient response to levodopa.
  • Cerebellar signs: Ataxia, wide-based gait, and balance problems are prominent, especially in the MSA-C subtype.
  • Early speech and swallowing difficulties are common and more severe than in typical Parkinson’s disease.

Autonomic Dysfunction

  • A hallmark of MSA is severe autonomic nervous system impairment, affecting involuntary functions such as blood pressure regulation, bladder and bowel control, and sweating.
  • Orthostatic hypotension (a significant drop in blood pressure upon standing) is common and can cause dizziness, syncope, and falls.
  • Bladder dysfunction often requires catheterization or medications.
  • Bowel dysfunction, including constipation, is frequent and challenging to manage.

Prodromal Symptoms

  • REM sleep behavior disorder (RBD) is a common early sign, characterized by vivid dreams with physical movements such as kicking or punching during sleep.
  • RBD can precede motor symptoms by years and is seen in both MSA and Parkinson’s disease.

Diagnostic Challenges

  • Diagnosis is difficult and often delayed by about 4 years from symptom onset.
  • Clinical criteria are used, as no definitive biomarker exists.
  • MRI may show the "hot cross bun sign" in the pons, a radiological clue suggestive of MSA, but it is not universally present.
  • Postmortem studies reveal diagnostic accuracy ranges from 62% to 79%, highlighting the complexity.

Disease Progression and Prognosis

  • MSA progresses more rapidly and aggressively than Parkinson’s disease.
  • Within 3 years, about 30% of patients require walking aids; by 5 years, 60% may be wheelchair-bound.
  • Frequent falls, severe speech and swallowing difficulties, and autonomic failure contribute to morbidity.
  • Quality of life is severely impacted, affecting both patients and caregivers.
  • Mortality is often related to complications such as aspiration pneumonia due to swallowing dysfunction or sudden autonomic failure.

Treatment and Management

Pharmacological Treatment

  • Levodopa remains the gold standard for Parkinson’s disease but offers limited and short-lived benefit in MSA.
  • High doses of levodopa may worsen orthostatic hypotension, requiring careful monitoring.
  • Medications to manage autonomic symptoms include:
    • Agents to raise blood pressure (e.g., fludrocortisone, midodrine) under medical supervision.
    • Bladder medications like mirabegron, though side effects must be considered.
    • Anticholinergic drugs or botox injections for drooling, with caution due to potential swallowing issues.

Non-Pharmacological Interventions

  • Multidisciplinary care is essential, involving neurologists, cardiologists, gastroenterologists, sleep specialists, psychologists, physical therapists, occupational therapists, and speech therapists.
  • Physical therapy aims to maintain mobility, improve gait and balance, prevent contractures, and reduce falls.
  • Occupational therapy supports daily living activities and home safety modifications (e.g., grab bars, removal of rugs).
  • Speech therapy addresses dysarthria and swallowing difficulties, recommending strategies like smaller meal volumes and posture adjustments.
  • Psychological support is critical for managing depression, anxiety, and caregiver stress.

Symptom-Specific Management

  • Pain management is important, as pain is common but often under-recognized.
  • Sleep disturbances, including stridor and obstructive sleep apnea, require evaluation by sleep specialists.
  • Constipation is managed with hydration, exercise, stool softeners, and dietary fiber, balancing benefits and bloating risks.

Research and Future Directions

  • Despite numerous studies, no disease-modifying treatments have been approved.
  • Over the past 40 years, about 50 high-quality double-blind placebo-controlled trials have been conducted, mostly targeting alpha-synuclein pathology.
  • Most trials have been negative, possibly due to late intervention, lack of biomarkers, and small patient populations.
  • Promising ongoing research includes:
    • Stem cell therapies (intrathecal mesenchymal and oral mucosal stem cells).
    • Monoclonal antibodies targeting alpha-synuclein.
    • Neurotrophic factors and small molecule inhibitors aimed at cell death pathways.
    • Antisense oligonucleotide (ASO) therapies.
  • Clinicaltrials.gov lists about 10 active trials worldwide, offering hope for future breakthroughs.

Summary and Take-Home Messages

  • MSA is a rare, rapidly progressive neurodegenerative disorder with complex motor, cerebellar, and autonomic features.
  • It is often misdiagnosed as Parkinson’s disease but differs in clinical course, treatment response, and prognosis.
  • Diagnosis relies on clinical criteria and supportive imaging; no definitive biomarker exists.
  • Management is multidisciplinary and focuses on symptom control, maintaining function, and improving quality of life.
  • Autonomic dysfunction is a major challenge requiring careful monitoring and treatment.
  • Research is ongoing, with emerging therapies targeting the underlying pathology.
  • Support for patients and caregivers, including psychological and social resources, is vital.

If you want, I can also help you create a detailed study guide or organize this information into sections for easier review. Just let me know!

Certainly! Here is an in-depth elaboration on autonomic dysfunction in Multiple System Atrophy (MSA), based on the lecture and related knowledge:

Autonomic Dysfunction in Multiple System Atrophy (MSA)

Overview

Autonomic dysfunction is a hallmark and one of the most debilitating features of Multiple System Atrophy (MSA). It involves impairment of the autonomic nervous system (ANS), which controls involuntary bodily functions such as blood pressure regulation, heart rate, bladder and bowel control, sweating, and digestion. This dysfunction significantly contributes to morbidity, impacts quality of life, and complicates management.

The Autonomic Nervous System (ANS)

  • The ANS regulates involuntary physiological processes.
  • It has two main branches:
    • Sympathetic nervous system: Prepares the body for "fight or flight" responses (e.g., increases heart rate, constricts blood vessels).
    • Parasympathetic nervous system: Promotes "rest and digest" activities (e.g., slows heart rate, stimulates digestion).
  • In MSA, both branches can be affected due to widespread neurodegeneration in brainstem and spinal autonomic centers.

Key Features of Autonomic Dysfunction in MSA

1. Orthostatic Hypotension (OH)

  • Definition: A significant drop in blood pressure upon standing (≥20 mmHg systolic or ≥10 mmHg diastolic).
  • Mechanism: Failure of the autonomic nervous system to constrict blood vessels and maintain blood pressure when moving from lying to standing.
  • Symptoms:
    • Dizziness or lightheadedness upon standing.
    • Syncope (fainting) or near-fainting episodes.
    • Fatigue and weakness.
  • Clinical Importance:
    • Major cause of falls and injuries.
    • Limits mobility and independence.
    • Requires careful monitoring during treatment, especially with levodopa, which can exacerbate hypotension.
  • Diagnosis:
    • Blood pressure measured after lying down for 5 minutes, then at intervals after standing (1, 3, 10 minutes).
    • A drop of ≥20 mmHg systolic or ≥10 mmHg diastolic confirms OH.
  • Management:
    • Increase fluid intake and salt consumption (under medical supervision).
    • Small, frequent meals to avoid postprandial hypotension.
    • Compression stockings or abdominal binders to reduce blood pooling.
    • Medications such as midodrine or fludrocortisone to raise blood pressure.
    • Elevate head of bed to prevent nocturnal hypertension.

2. Bladder Dysfunction

  • Symptoms:
    • Urinary urgency, frequency, and incontinence.
    • Difficulty emptying the bladder (urinary retention).
  • Mechanism:
    • Neurodegeneration affects the autonomic control of bladder function.
    • Both detrusor muscle (bladder wall) and sphincter control can be impaired.
  • Clinical Impact:
    • May require intermittent self-catheterization multiple times daily.
    • Increases risk of urinary tract infections.
    • Significantly affects quality of life.
  • Treatment:
    • Medications such as mirabegron (a beta-3 adrenergic agonist) to relax bladder muscle.
    • Anticholinergic drugs may be used cautiously but can worsen other symptoms.
    • Catheterization when necessary.
    • Regular urological evaluation.

3. Bowel Dysfunction

  • Symptoms:
    • Constipation is common and often severe.
  • Mechanism:
    • Impaired autonomic regulation of gastrointestinal motility.
  • Management:
    • Increased hydration and dietary fiber (balanced to avoid bloating).
    • Regular physical activity.
    • Use of stool softeners or laxatives as needed.
    • Careful monitoring to avoid complications.

4. Sweating Abnormalities

  • Symptoms:
    • Reduced or absent sweating (anhidrosis) in some areas.
    • Excessive sweating (hyperhidrosis) in others.
  • Impact:
    • Can affect temperature regulation.
    • May cause discomfort and skin problems.

5. Cardiovascular and Respiratory Effects

  • Heart Rate Variability:
    • Loss of normal autonomic modulation can cause abnormal heart rate responses.
  • Stridor and Sleep-Related Breathing Disorders:
    • Autonomic dysfunction can contribute to respiratory problems, including stridor (noisy breathing) and obstructive sleep apnea.
    • These can worsen prognosis and require sleep specialist evaluation.

Challenges in Managing Autonomic Dysfunction in MSA

  • Complexity: Multiple systems are involved simultaneously, requiring a multidisciplinary approach.
  • Medication Side Effects: Treatments for motor symptoms (e.g., levodopa) can worsen autonomic symptoms like orthostatic hypotension.
  • Monitoring: Blood pressure and bladder function require regular assessment.
  • Patient Safety: Risk of falls and injuries due to dizziness and syncope necessitates home safety evaluations and caregiver support.
  • Quality of Life: Autonomic symptoms severely impact daily functioning and independence.

Multidisciplinary Approach to Autonomic Dysfunction

  • Neurologists: Coordinate overall care and adjust medications.
  • Cardiologists: Manage blood pressure abnormalities and cardiac autonomic failure.
  • Urologists: Address bladder dysfunction and catheterization needs.
  • Gastroenterologists: Help manage bowel issues.
  • Physical and Occupational Therapists: Assist with mobility, fall prevention, and adaptive strategies.
  • Nurses and Caregivers: Provide education and support for symptom management.
  • Psychologists and Social Workers: Address emotional and social challenges related to chronic autonomic symptoms.

Summary

Autonomic dysfunction in MSA is a multifaceted and severe problem involving:

  • Orthostatic hypotension causing dizziness, falls, and syncope.
  • Bladder and bowel dysfunction leading to incontinence, retention, and constipation.
  • Sweating abnormalities affecting thermoregulation.
  • Cardiovascular and respiratory complications impacting survival.

Effective management requires early recognition, careful monitoring, lifestyle modifications, pharmacological interventions, and a coordinated multidisciplinary team to improve patient safety, function, and quality of life.

If you want, I can help you create a detailed management plan or study guide focused specifically on autonomic dysfunction in MSA. Just let me know!

Full transcript